Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 12, 258 (1 March 2006) | doi:10.1038/nm0306-258b;
One year after launch, drug safety board is dubbed a failure
Abstract
A new drug safety board at the US Food and Drug Administration (FDA) is failing in its declared goal of increasing openness and transparency at the agency, members of an FDA advisory committee said in February. Exactly a year ago, the FDA announced with much fanfare the launch of a new panel aimed at improving the agency's management of drug safety issues—including releasing early warnings when safety issues begin to emerge.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).